Search results for "Pharmacotherapy"

showing 10 items of 283 documents

Reactivación de hepatitis B en paciente con hepatitis crónica C tratado con antivirales de acción directa

2018

Hepatologybusiness.industryGastroenterologyHepatitis CHepatitis Bmedicine.diseaseDIRECT ACTING ANTIVIRALSVirology03 medical and health sciences0302 clinical medicinePharmacotherapyChronic hepatitis030220 oncology & carcinogenesismedicine030211 gastroenterology & hepatologybusinessViral loadGastroenterología y Hepatología
researchProduct

DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa???1)

2003

Infanrix hexaPharmacotherapybusiness.industryDtpa hbv ipv hibPharmacology toxicologyMedicinePharmacology (medical)businessVirologyDrugs
researchProduct

Left Ventricular Remodelling Conditions Left Atrial Volume and Function In Hypertensive Patients? Evaluation in RT3D Echocardiography

2007

Left ventricular massmedicine.medical_specialtyPharmacotherapybusiness.industryInternal medicineInternal MedicineCardiologyMedicineRenal functionCardiology and Cardiovascular MedicinebusinessHigh Blood Pressure & Cardiovascular Prevention
researchProduct

Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany

2011

The incidence of cutaneous and mucocutaneous Leishmaniasis (CL/MCL) is increasing globally, also in Germany, although the cases are imported and still low in number. The current evidence for the different therapies has many limitations due to lack of sufficient studies on the different Leishmania species with differing virulence. So far there is no international gold standard for the optimal management. The aim of the German joint working group on Leishmaniasis, formed by the societies of Tropical Medicine (DTG), Chemotherapy (PEG) and Dermatology (DDG), was to establish a guideline for the diagnosis and treatment of CL and MCL in Germany, based on evidence (Medline search yielded 400 artic…

Leishmaniasis Mucocutaneousmedicine.medical_specialtymedicine.medical_treatmentParomomycinCryotherapyDermatologyPharmacotherapyCutaneous leishmaniasisPregnancyGermanyparasitic diseasesmedicineHumansMiltefosineAntiparasitic Agentsbusiness.industryLeishmaniasismedicine.diseaseDermatologyLymphangitisPregnancy Complications ParasiticFemaleDermatologic AgentsbusinessFluconazolemedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial

2007

Abstract BACKGROUND/AIMS: Risks and benefits of antiviral therapy in HCV cirrhosis with portal hypertension are poorly known. METHODS: We performed a randomized controlled trial in 102 HCV patients with compensated cirrhosis and portal hypertension: 51 received 1 microg/kg/week of Pegylated-interferon alpha-2b and 51 Pegylated-interferon plus 800 mg/day of ribavirin up to 52 weeks. RESULTS: By intention-to-treat analysis, five patients on monotherapy and eleven on combination therapy achieved a sustained virological response (9.8% vs. 21.6%, p=0.06). The response was more frequent for genotypes 2 or 3 than genotype 1 (66.6% vs. 11.3%, p=0.001). Genotype 1, who had low viral load at start of…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCombination therapyAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene GlycolsCirrosi epatica da HCV terapia antivirale.chemistry.chemical_compoundPharmacotherapyInternal medicineHypertension PortalRibavirinmedicineHumansAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomechemistryPortal hypertensionRNA ViralDrug Therapy CombinationbusinessViral load
researchProduct

Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study

2020

Background and aims: Familial hypercholesterolaemia (FH) is a powerful risk factor for cardiovascular (CV) events. High levels of low-density lipoprotein cholesterol (LDL-C) since birth are linked to the early onset of atherosclerotic disease. A genetic mutation determining FH is present in about one subject out of 250; FH should be more represented among subjects with a documented diagnosis of coronary artery disease (CAD). The POSTER Study evaluated the prevalence of FH in Italian patients with a recent CAD event. Methods: Eighty-two cardiology centres enrolled patients with a documented CAD event; CV risk profile, drug therapy and biochemical parameters were collected. Dutch Lipid Clinic…

Male0301 basic medicineAcute coronary syndromemedicine.medical_specialtySettore MED/09 - Medicina InternaFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyCoronary revascularizationCoronary artery diseaseHyperlipoproteinemia Type IICoronary artery disease03 medical and health sciences0302 clinical medicinePharmacotherapyRisk FactorsInternal medicinePrevalencemedicineHumansLow-density lipoprotein cholesterolMyocardial infarctionRisk factorAgedHigh prevalencebusiness.industryCholesterol LDLMiddle Agedmedicine.diseaseCoronary revascularizationMyocardial infarction030104 developmental biologyItalyDutch lipid clinic networkCardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats

2021

Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N-acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain homeostasis of the glutamate system disrupted in addiction. However, there is little evidence in the case of alcohol. The aim of this study was to explore the potential anti-relapse efficacy of NAC using the alcohol deprivation effect (ADE) model in long-term experienced rats. Two experiments were performed in male Wistar rats to: (a) test the effic…

Male0301 basic medicineDrugAlcohol DrinkingInjections Subcutaneousmedia_common.quotation_subjectDrug Evaluation PreclinicalAlcoholPharmacologyInfusions Subcutaneous:CIENCIAS DE LA VIDA [UNESCO]ethanol relapse preventionAcetylcysteineRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundSubcutaneous injection0302 clinical medicinePharmacotherapyalcohol use disordersRecurrenceglutamate neurotransmissionUNESCO::CIENCIAS DE LA VIDAAnimalsMedicineRats Wistarmedia_commonEthanolEthanolbusiness.industryAbstinencealcohol deprivation effecAcetylcysteineRatsSubstance Withdrawal SyndromeAlcoholismRegimen030104 developmental biologychemistryModels Animalbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

From Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines to Current Clinical Practice

2006

Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have been promulgated to improve the management of chronic obstructive pulmonary disorder (COPD). Objective: To evaluate the extent to which the current therapeutic approach to COPD conforms to GOLD guidelines. Methods: This was a multicentre observational study of elderly COPD patients enrolled for acute care in general medicine or geriatric wards in tertiary hospitals in Italy in April 2002. Our series consisted of 471 patients >64 years of age consecutively admitted for acute exacerbations of COPD to wards participating in the study. Data describing drugs used prior to exacerbation and prescribed at …

MaleAgingmedicine.medical_specialtyDrug IndustryPharmacological therapyGuidelines as Topicurologic and male genital diseasesPulmonary Disease Chronic ObstructivePharmacotherapyOdds RatiomedicineHumansMulticenter Studies as TopicPharmacology (medical)Practice Patterns Physicians'Intensive care medicineAgedCOPDbusiness.industryRespiratory diseaseTiotropium bromidemedicine.diseaseDrug UtilizationObstructive lung diseaserespiratory tract diseasesClinical PracticeLung diseasePhysical therapyFemaleGuideline AdherenceAcute Exacerbation Tiotropium Methylxanthine Tiotropium Bromide Cumulative Illness Rate ScaleGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

2006

Background: Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA). Methods: A multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another systemic antifungal agent. Criteria for IA and therapeutic responses were judged by an independent panel. Results: Of the 331 patients enrolled, only 225 met diagnos…

MaleAntifungal Agentsmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationAspergillosisGastroenterologyEchinocandinsAmphotericin BChildAged 80 and overResearch Support Non-U.S. Gov'tMiddle AgedLipoproteins [administration & dosage]Infectious DiseasesChild PreschoolAcute DiseaseCombinationDrug Therapy CombinationFemalemedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyAdolescentEchinocandinLipoproteinsBiologyAntifungalPeptides CyclicArticleLipopeptidesPharmacotherapyInternal medicineAmphotericin BmedicineHumansAspergillosisEchinocandinAgedChemotherapyAspergillosis [drug therapy]MicafunginInfantmedicine.diseasebacterial infections and mycosesSurgeryPeptides Cyclic [administration & dosage]MicafunginAntifungal Agents [administration & dosage]
researchProduct

Pruritus characteristics in a large Italian cohort of psoriatic patients

2019

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…

MaleCross-sectional studySeverity of Illness IndexCohort Studies030207 dermatology & venereal diseases0302 clinical medicineRisk Factorseducation; itch; pruritus; psoriasis; pustular psoriasis; treatment; Adolescent; Adult; Cohort Studies; Cross-Sectional Studies; Educational Status; Facial Dermatoses; Female; Foot Dermatoses; Genitalia; Hand Dermatoses; Humans; Italy; Male; Middle Aged; Pruritus; Psoriasis; Registries; Risk Factors; Severity of Illness Index; Sex Factors; Young AdultEpidemiologyitchRegistriesYoung adultskin and connective tissue diseaseseducationtreatmentMiddle AgedSettore MED/33 - MALATTIE APPARATO LOCOMOTOREInfectious Diseasespustular psoriasisItaly030220 oncology & carcinogenesisCohortEducational StatusPRURITIS EPIDEMIOLOGYFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREECohort studyAdultmedicine.medical_specialtyAdolescentPSORIASDermatologyHand DermatosesArticle03 medical and health sciencesYoung AdultPharmacotherapySex FactorsSettore MED/35PsoriasisSeverity of illnessmedicineHumansPsoriasisGenitaliaFoot Dermatosesbusiness.industryPruritusmedicine.diseaseDermatologyPruritusItch sensationCross-Sectional StudiesbusinessFacial Dermatoses
researchProduct